deltatrials
Completed PHASE1 NCT01274455

Gene Therapy of Pancreatic Ductal Adenocarcinoma

PILOT STUDY OF GENE THERAPY FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA WITH INTRATUMOURAL INJECTION OF JetPEI/DNA COMPLEXES WITH ANTITUMOURAL EFFECT AND CHEMOSENSITIZING ACTIVITY FOR GEMCITABINE

Sponsor: CAYLA-INVIVOGEN

Conditions Pancreatic Adenocarcinoma
Interventions Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes
Updated 5 times since 2017 Last updated: Mar 11, 2016 Started: Dec 31, 2010 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

A PHASE1 clinical study on Pancreatic Adenocarcinoma, this trial is completed. The trial is conducted by CAYLA-INVIVOGEN and has accumulated 5 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CAYLA-INVIVOGEN
  • Clinical Research Center, Toulouse
  • Institut National de la Santé Et de la Recherche Médicale, France
  • University Hospital, Toulouse
Data source: University Hospital, Toulouse

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Toulouse, France